Want to join the conversation?
$BCR, which competes with $COV, said it will benefit from incremental revenue in 2016 from the acquisitions of its Japanese JV and Liberator Medical. The company also expects to see a non-operating reduction to revenue from lower sales of EP products to $BSX and it is prepared for a range of levels for the Gore royalty.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)